November 13, 2019
A raft of new medicines will be added to Japan’s NHI price list on November 19, with a key reimbursement policy panel giving them the go-ahead on November 13 including Astellas Pharma’s first-in-class renal anemia drug Evrenzo (roxadustat) and Takeda...read more